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Background: The deregulation of microRNAs in both tumours and blood has led to the search for microRNAs to
indicate the presence of cancer and predict prognosis. We hypothesize the deregulation of miR-200c/miR-141 in
the whole blood can identify breast cancer (BC), and could be developed into a prognostic signature.
Methods: The expression of miR-200c and miR-141 were examined in bloods (57 stage I-IV BC patients and 20
age-matched controls) by quantitative reverse-transcription PCR. The associations of circulating microRNAs with
clinic and pathological characteristics were analysed. Their effects on survival were analysed by the Kaplan-Meier
method and Cox regressions.
Results: MiR-200c was down regulated (P < 0.0001) in the blood of BC patients, yielded an area under the ROC
curve of 0.79 (90% sensitivity, 70.2% specificity) in discriminating BC from controls. Circulating miR-141 was not
discriminating. MiR-200c and miR-141 in the blood of BC patients were inversely correlated (P = 0.019). The miR-200c
levels were numerically higher in stage IV and tumours with lower MIB-1. MiR-141 was significantly higher in the blood
of patients with stage I-III, lymph node metastasis, and HER2 negative tumours. High blood expression of miR-200c
and/or low expression of miR-141 was associated with unfavourable overall survival (hazard ratio, 3.89; [95% CI:
1.28-11.85]) and progression-free survival (3.79 [1.41–10.16]) independent of age, stage and hormonal receptors.
Conclusions: Circulating miR-200c and miR-141 were deregulated in BC comparing with controls. Furthermore,
miR-200c and miR-141 were independent prognostic factors and associated with distinct outcomes of BC patients.
Keywords: Breast neoplasm, microRNAs, Blood, Biomarkers, Prognostic factorsBackground
Breast cancer (BC) is the leading cause of cancer death
in women worldwide, accounting for 458,400 deaths in
2008 [1]. Relative survival from BC in women has im-
proved steadily in all developed countries over the past
25 years. By (2012), it was estimated that Spain would
have a total of 27,000 new diagnoses of BC among
women and currently BC remains the leading cause of
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Cancer progression and blood-borne metastasis con-
tribute to the great majority of BC deaths. The discovery
of specific biomarkers characterizing the metastatic
phenotype holds the promises of personalised therapy
and improved prognosis prediction in many neoplastic
diseases including BC.
Tumour tissue based biomarkers (e.g. size, grade, node
status, hormone receptor status, HER2, Ki-67) are widely
used in the clinical practice in BC. In addition, gene
expression signatures of breast carcinomas have led to
new classifications of tumour subgroups and also carry
prognostic and predictive information [3]. In contrast,
although serum tumour markers, including carcinoem-
bryonic antigen, CA 15.3 and CA 27.59 could provide. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ommended for screening, diagnosis, or routine surveil-
lance after initial treatment [4].
A large amount of data has revealed the correlation
between specific tumours and differential microRNA
(miRNA) expression profiles, thus providing a new class
of disease-specific biomarkers (revised in [5]). MiRNAs
are 18- to 25-nt noncoding RNA molecules that regulate
protein expression of specific mRNA by either transla-
tional inhibition or mRNAs degradation. MiRNAs play
different regulatory roles in cancer and have distinct
functions in controlling the cell cycle, proliferation, inva-
sion and metastasis. Moreover, miRNA deregulation can
induce a pro-inflammatory and pro-metastatic environ-
ment and curtail the anti-tumour immunity [6,7].
An increasing number of studies analysing the miRNA
expression signatures in BC, their correlates with spe-
cific molecular subtypes and their potential clinical rele-
vance have been reported [8-11].
The miR-200 family of miRNAs consists of five mem-
bers grouped in two independent transcriptional clus-
ters: miR-200a, 200b and 429, located on chromosome
1p36; and miR-200c and 141, located on 12p13. Deregu-
lation of miR-200 family of microRNAs in cancer [12,13]
has been related to epithelial to-mesenchymal transition
and cell-plasticity, apoptotic response, molecular sub-
type, oestrogen regulation, control of the growth and
function of stem cells and regulation of the downstream
transcriptional program that mediate distant metastasis.
Also, regulatory functions of miR-200 s in tumour
angiogenesis have been recently described [14]. However,
in vitro and functional studies have yielded conflicting
results regarding the net effect of miR-200 s in suppress-
ing or promoting metastasis in different cellular contexts
and cancer types [15-17].
MicroRNAs can be detected in the blood and studies
indicate they are particularly stable and abundant [18,19].
Circulating miRNAs could be actively secreted from
tumour cells, but also from non-malignant cells, including
immune cells, either microvesicle-associated or free, in a se-
lective manner [20]. In addition, passive leakage derived of
apoptosis or necrosis of cancer cells tissue or chronic in-
flammation could be the source of microRNA founded in
total blood, serum or plasma.
Our previous study has shown miR-200c in the blood
can distinguish with significant specificity and sensitivity,
patients with gastric cancer from healthy controls and re-
markably, increased expression levels of miR-200c in blood
were significantly associated with poor progression-free and
overall survivals in gastric cancer patients [21].
Only a few studies have directly examined the role of
miRNAs in the prognosis in BC, the vast majority of
which were conducted analysing miRNA expression in
the primary breast tumour (revised in [22]). However,little is known concerning the relationship between the
blood miRNA expression profiles with the prognosis in
BC patients. We first performed a Phase I preclinical
study by means of computational tools for miRNAs pro-
filing. Selected miRNAs were evaluated by RT-qPCR in
BC and hematopoietic cell lines, control bloods, and
blood from metastatic BC patients. Based on these re-
sults miR-141 and mir-200c were chosen for further
analysis in BC patients [23].
Hence, we hypothesised that the quantitative detection
of the miR-200 family in the whole blood could be
useful as clinical biomarker in BC patients. In that
sense, the blood miR-200 cluster expression might
correlate with BC diagnosis, staging and prognosis. In
the present study, we found that miR-200c and miR-
141 expression levels were deregulated in the blood of
BC patients. Likewise, the blood levels of miR-200c
and miR-141 emerged as compelling and independent
prognostic signature for the progression and survival
of BC patients.
Methods
Participants
Consecutive female BC outpatients were included from
the medical oncology unit at University hospital in La
Coruña, Spain. Inclusion criteria were: Confirmed patho-
logic diagnosis of invasive BC; stage I–III with no prior
systemic therapy; stage IV patients with no previous sys-
temic therapy or in confirmed progression after such
treatment; written informed consent.
Exclusion criteria were defined as: previous invasive non-
breast cancer; coagulopathies or platelets< 20,000 × 109/L;
any previous systemic therapy for BC except relapsed or
stage IV patients with confirmed progressive disease; prior
pelvic radiation; previous bisphosphonate therapy.
The diagnostic work-up included clinical examination,
blood sampling with CA 15.3 serum determination, mam-
mography, chest x-ray, abdominal ultrasound and
bone scan. Computed tomography scanning of the
chest, abdomen and pelvis was performed on stage IV
patients.
The patients were followed up clinically every 3 months
during the first 2 years, every 6 months for 3 years and in a
yearly basis afterwards to monitor disease progression.
Mammographic evaluation was performed every year dur-
ing all the follow up period.
The controls (all females) were recruited from the pa-
tients’ family and relatives. We only excluded subjects
with a previous history of malignant disease. Thus, con-
trols with different chronic but stable diseases (e., hyper-
tension, diabetes mellitus or heart disease) were eligible
and consecutively recruited. The control cohort was
selected to include an age distribution that was compar-
able to the patient group.
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verse transcription PCR (RT-qPCR) analysis was col-
lected in EDTA-containing tubes (10 mL). The first
5 mL of collected blood was discarded to avoid contam-
ination with epidermal cells. Then, the PB was further
diluted in RNAlater and frozen at −20°C for storage
until RNA extraction
This study was approved by the Ethics Committee of
Clinical Investigation of Galicia (Spain) and conducted
in compliance with the Helsinki Declaration. Written in-
formed consents were obtained from all the patients and
the controls prior to their inclusion in the study.
Pathological analyses
The primary tumour and axillaries lymph nodes col-
lected during surgery were processed on a routine diag-
nostic basis. Histological type, tumour size and nodal
involvement were analysed, and the disease was staged
according to the TNM system [24]. Tumour grading was
performed according to modified Bloom–Richardson
score. Immunohistochemistry (IHC) was performed for
oestrogen receptor (ER), progesterone receptor (PgR),
Ki-67antigen (MIB-1) and HER2. Immunopositivity was
recorded when 10% (ER, PgR) of the nucleus of tumour
cells were stained. HER2 required distinct membranous
staining for being considered positive (3+). The HER2
status of tumours with an IHC score of 2+ was deter-
mined by the fluorescence in situ hybridization results.
Residual disease status at the time of blood sampling
was classified as R0 when no residual disease was
present after surgery, R1 when microscopic residual dis-
ease was found and R2 in the presence of macroscopic
disease. The patients from whom the blood was obtained
before the start of neoadjuvant treatment were cate-
gorised as R2. When surgery was not performed, the
pathological diagnosis was based on radiological-guided
biopsies.
Blood microRNA isolation and reverse-transcription quan-
titative PCR (RT-qPCR)
MiRNA extraction from blood was performed with the
RiboPure-Blood Kit (Ambion Inc, Austin, TX). The pro-
cedure was performed using 0.5 mL of whole blood. The
mirVanaTM RT-qPCR miRNA Detection Kit (Ambion
Inc, Austin, TX) was used to detect and quantify miRNA
expression. To control input variability and sample nor-
malisation, primer sets specific for the small RNA spe-
cies U6 snRNA (Ambion, AM30303) and 5S rRNA
(Ambion, AM30302) were used. Real-time PCR was per-
formed on the LightCycler® 480 Instrument (Roche,
Mannheim, Germany).
The Relative Expression Software Tool (REST) was
used to analyse the relative miRNA expression in each
sample and to determine the fold difference for everymiRNA [25]. The expression levels of the target miRNAs
were standardised using an index containing 5S rRNA
and U6 snRNA.
All the procedures have been described previously
[21]. For details, refer to Additional file 1.
MiRNA analyses were performed with no knowledge
of the clinical or follow-up data.
Bioinformatics and microRNAs expression profiling
MiRNA expression data from previously published BC
cohorts [9,10] were retrieved. Selected microRNAs, miR-
200c and miR-141 were analysed further to assess
whether they were associated with clinic and pathologic
factors.
The online tool MIRUMIR [26] was used to estimate
the power of miR-200c and miR-141 tumour expression
to serve as potential biomarkers to predict survival of
BC patients. MIRUMIR performs survival analyses
across several available data sets. False discovery rate
control procedure is implemented to adjust P-values for
multiple testing. MIRUMIR is freely available at http://
www.bioprofiling.de/MIRUMIR.
In addition, the PROGmiR tool [27] available at http://
www.compbio.iupui.edu/progmir was also used to study
overall survival implications for miR-200c and miR-141
in BC. The BC expression data comes from The Cancer
Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/tcga).
This dataset include survival data of 727 cases of invasive
breast carcinoma. MicroRNA expression data was obtained
using the Illumina Genome Analyzer (GA) and HiSeq
platforms.
Finally, to more comprehensively profile circulating
miR-141 and miR-200c as potential markers of BC, we
obtain their expression in serum, plasma or total blood
in the genome-wide studies deposited in NCBI’s Gene
Expression Omnibus (GEO) [28]. The values of the
specific miRNAs were retrieved through of the GEO2R
web application, available at http://www.ncbi.nlm.nih.-
gov/geo/geo2r/.
Study design and statistical analyses
The primary aims were to estimate the diagnostic accur-
acy and usefulness of miRNA as measured by RT-qPCR
in the blood of BC patients as a clinical biomarker and
to determine its potential prognostic value. The study
was performed following the proposed guidelines of the
Early Detection Research Network [29]. The design and
results are presented in accordance with the REMARK
[30] and MIQE guidelines [31].
The potential correlation among blood miRNA levels
and the clinical and pathological features of the study
subjects were analysed. The normality of the distribution of
miRNA expression was analysed using the Kolmogorov-
Smirnov test. Thus, parametric or non-parametric statistics
Table 1 Characteristics of subjects included in the study
Characteristic Patients Controls
n = 57 (%) n = 20 (%)
Age (years, mean ± SD) 55.4 ± 12.8 54.8 ± 14.3 0.853*
<55 28 (49) 12 (60) 0.48**
≥55 29 (51) 8 (40)
Menopause
Pre-menopausal 24 (42.1) N/A
Post-menopausal 33 (57.9) N/A
Histology
Ductal 50 (87.7)
Lobular 5 (8.8)
Other 2 (3.5)
Histological grade
1 7 (12.3)
2 25 (43.9)
3 23 (40.4)
TNM Stage
I 14 (24.6)
II 13 (22.8)
III 17 (29.8)
IV 13 (22.8)
Lymph nodes involved
No 20 (35.1)
Yes 37 (64.9)
Hormonal Receptors
Positive 42 (73.7)
Negative 14 (24.6)
HER2
Positive 14 (24.6 )
Negative 42 (73.7 )
MIB1
<25% 40 (70.2)
>25% 14 (24.6)
Type
Luminal 32 (56.1)
HER2 14 (24.6)
Triple negative 10 (17.5)
R0 28 (49.1)
R2 29 (50.9)
Abbreviation: ECOG Eastern Cooperative Oncology Group performance status.
Residual Status (R): R0, no residual tumour; R2, macroscopic residual tumour.
The number (percentages) of patients with data avalaible is indicated.
*Student t-test. **Chi2 test.
Antolín et al. BMC Cancer  (2015) 15:297 Page 4 of 15were used, as appropriate. The relationships between miR-
NAs levels and the quantitative clinical variables were ana-
lysed using the Spearman correlation. The Cutoff Finder
software [32] was used for receiver operating characteristic
(ROC) curves analysis and miRNAs expression cutoffs
determinations. The ROC curves were constructed by plot-
ting sensitivity (Y-axis) vs 1-specificity (X-axis) and the
areas under the curve (AUC) were calculated. The method
used was based on the maximization of Youden’s J
statistics. In this first step, the cutoff is optimized for
discriminating controls and BC patients based on
miRNAs expression. In the second step, the Cutoff
Finder tool fits Cox proportional hazard models to the
dichotomized miRNA expression in the BC cohort and
the survival variables (OS and PFS). These prognostic
cutoffs are defined as the points with the most signifi-
cant (log-rank test) split. Hazard ratios (HRs) includ-
ing 95% confidence intervals are calculated to assess
the stability and significance of the dichotomization.
Significances of correlations with overall survival (OS)
and progression-free survival (PFS) were determined.
PFS was measured as the time between the baseline
blood sampling for miRNA analysis and the documenta-
tion of first BC progression, based on clinical and radio-
logical findings, second primary tumour or death from
any cause (events). OS was measured from the time at
which the baseline blood sample was obtained to the
date of death from any cause or date of last follow-up.
The patients who were alive and progression-free at the
time of analysis were censored by using the time be-
tween the blood assessment and their most recent
follow-up evaluations.
Multivariate survival analyses (PFS and OS) were per-
formed using Cox regression models. All statistical tests
were two-sided and P values less than 0.05 were consid-
ered significant. SPSS Statistics 19.0 for Windows (IBM
Corporation, Armonk, NY, USA, 2011) and Graph Pad
Prism 5 (GraphPad Software, La Jolla, CA, USA, 2007)
were used for data analyses.
The statistical power of the study was estimated post-hoc,
taking into account a probability of survival at the end of
the study of 0.75 in the low-risk miRNA signature group
and 0.35 in the poor-prognostic subgroup. The poor-
prognostic subgroup was defined by an increased expres-
sion of miR-200c and/or down-regulation of miR-141 in
the patient’s bloods. With the sample size of 57 patients,
the study was able to demonstrate by two-sided log-rank
test, a significant difference in OS, with an alpha-error of
0.05 and a statistical power higher than 80%.
Results
Patients and clinical data
From November 2006 to May 2008, 57 female patients
with histological proven BC were consecutively recruitedfor this study. The control cohort included 20 cases. The
clinical characteristics of the included subjects are
shown (Table 1). The mean age was 54.8 years (standard
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the control group and 55.4 years (S.E.M., 1.7; range, 27
to 83) in the patient group (t test, P = 0.853).
The blood was obtained after R0 surgery in 28 patients
(49.1%). In 29 (50.9%) patients, the blood samples were
obtained before neoadjuvant treatment or in the pres-
ence of metastatic disease, both of which were cate-
gorised as R2 at the time of blood sampling.
All patients were followed until death or study com-
pletion. The last date of follow-up for the survivors
was April (2013). Disease progression events occurred
in 22 patients (38.6%). The mean PFS was 235.3 weeks
(95% CI: 203.6 to 267 weeks). There were 10 progres-
sions among stage I–III patients and 12 progressions
of metastatic disease. The mean OS was 264.6 weeks
(95% CI: 239.2 to 290 weeks) and 19 patients (33.3%)
died. The mean (S.E.M.) follow-up time for the pa-
tients still alive at the time of the analysis was 298.2
(2.7) weeks (median, 303.7 weeks; 95% CI: 296.6 to
310.8 weeks).Expression of miRNA in blood samples
Real-time PCR quantitative assessment of miR-141
and miR-200c were performed using 77 blood samples
(57 patients and 20 controls). The Figure 1 depictsFigure 1 Real time PCR of miR-200c and miR-141 in blood samples. Plots d
miR-200c (C) between patients and healthy controls, and between stage I-III pa
denotes the mean value for each group. The corresponding P values are providrelative expression for the blood levels of miR-141 and
miR-200c.
The blood expression of miR-141 was not significantly
(P = 0.557) different in patients compared to healthy
controls (Figure 1A). The mean relative miR-141 expres-
sion (Figure 1B) was 2.615 (S.E.M., 0.83; 95% CI: 0.89 to
4.34) in controls, 8.81 (S.E.M., 2.29; 95% CI: 4.2 to 13.4)
in stage I-III patients and 1.06 (S.E.M., 0.93; 95% CI: 0
to 3.09) in stage IV BC patients (P = 0.003 Kruskal-
Wallis test. Dunnett’s multiple comparison tests: stage
I-III vs control, P = 0.099; stage IV vs control, P =
0.904). However, the blood levels of miR-141 could
not discriminate BC patients from healthy women in
ROC analysis.
We compared the expression levels of circulating
miR-200c in controls and BC patients. Our data showed
miR-200c was downregulated in the blood of BC pa-
tients by comparison with its expression in the blood of
controls (P < 0.0001; Figure 1C). Next, we sought to
identify potential differences of the expression levels of
miR-200c according to stage. The mean relative miR-
200c expression (Figure 1D) was 2.53 (S.E.M., 0.58; 95%
CI: 1.31 to 3.74) in controls, 0.41 (S.E.M., 0.13; 95% CI:
0.16 to 0.66) in stage I-III patients and 1.75 (S.E.M., 0.62;
95% CI: 0.41 to 3.09) in stage IV BC patients (P < 0.0001;
Kruskal-Wallis test. Dunnett’s multiple comparisonepicting the relative expression for blood levels of miR-141 (A) and
tients, stage IV patients and healthy controls (B and D). The horizontal bar
ed in plots.
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trol, P = 0.342).
ROC curve analysis (Figure 2A) showed that the blood
levels of miR-200c might serve as negative biomarker for
discriminating BC patients from healthy controls, with
an AUC (the area under the ROC curve) of 0.79 (95%
CI: 0.688 to 0.914; P <0.001). At the cut-off value of
0.165, the sensitivity and specificity were 90.0% and
70.2%, respectively. The odds ratio (OR) according to
the cut-off value (Figure 2B) was 0.62 (95% CI: 0.45-
0.85; P < 0.0001).
The ROC curve analysis using blood miR-200c yielded
an AUC of 0.850 (95% CI: 0.738 to 0.957; P < 0.001; OR:
0.37) in discriminating stage I-III BC from healthy con-
trols as shown in Figure 2C and D. When comparing the
relative miR-200c levels in controls and stage I-II pa-
tients (Figure 2E and F), the AUC was 0.82 (95% CI:
0.694 to 0.945; P < 0.001; OR: 0.45) with a sensitivity of
90%, and a specificity of 75%.
Clinical and pathological characteristics and miRNA levels
in the blood
The clinical and pathological characteristics and the
miR-200c and miR-141 expression levels in the blood
from BC patients are given (Table 2). The correlations of
quantitative clinical and laboratory parameters and miR-
NAs levels are summarized (Table 3). The miR-200c
levels were not related to any of the clinical and patho-
logical characteristics analysed. There was a tendency
(P = 0.054) to higher levels in the stage IV group com-
pared to stages I-III group. MiR-141 levels were signifi-
cantly higher in the blood of the patients with lymph
node metastasis (P = 0.014) and HER2 negative tumours
(P = 0.037). In stages I to III BC patients, we evaluated
the miR-200c and miR-141 levels according to timing of
blood sampling (post- vs. pre-operative). The levels of
each miRNA in the post- operative vs. pre-operative
samples were not significantly different (Table 2). How-
ever, the pre-and post-resection samples were not paired
from the same patients.
The Spearman order correlation analysis showed that
miR-200c expression in the blood of BC patients was
inversely correlated with the miR-141 level (rs = −0.311,
P = 0.019). In the control group however, there was no
correlation between miR-141 and miR-200c (rs = 0.006,
P = 0.98).
Prognostic significance of miR-200c and miR-141 levels in
the blood
The HRs for PFS and OS were first estimated consider-
ing the actual values of every miRNA as a continuous
variable in a Cox regression model. Increasing values for
miR-200c were associated with PFS events (HR 1.37;
95% CI: 1.09-1.71; P = 0.007) and reduced OS (HR 1.38;95% CI: 1.11-1.71; P = 0.003). In contrast, the miR-141
levels as a continuous variable were not significantly as-
sociated with outcomes (HR for PFS, 0.987; 95% CI:
0.95-1.025; P = 0.498. HR for OS, 0.986; 95% CI: 0.942-
1.032; P = 0.542).
To generate survival curves, we converted continuous
miRNAs expression values to dichotomous variables,
using the Cutoff finder software [32]. This procedure en-
abled division of samples into classes with high and low
expression of microRNA.
Using this approach, miR-141 was down-regulate in
the blood of 26.3% (15/57) of the patients. The percent-
age of patients with miR-141 down-regulation was asso-
ciated with TNM stage: 18.2% (8/44) in stage I-III
patients and 53.8% (7/13) in stage IV patients (Fisher’s
exact test, P = 0.027). In contrast, high expression of
miR-200c was found in 24.6% of the patients (14/57).
This overexpression was also associated with stage IV
(53.8% of the patients; Fisher’s exact test, P = 0.01).
The Kaplan-Meier analysis and the log-rank test were
used to calculate the effect of miR-200c and miR-141
blood expression on patient survival (Figures 3 and 4).
Specifically, the mean overall survival and progression-
free survival time of patients whose bloods expressed
high levels of miR-200c (>1.29 relative expression value)
was 201.48 weeks (median, 158.29 weeks) and 162.84 weeks
(median, 89.43 weeks) respectively, whereas the mean OS
and PFS time of those with low levels of miR-200c expres-
sion was 284.7 weeks (log-rank P =0.004) and 258.85 weeks
(long-rank P =0.022), respectively (Figure 3B and D). The
median was not reached in the low miR-200c subgroup. A
significant association between a high miR-200c blood level
and poor PFS (HR 3.33; 95% CI: 1.22 to 9.07; P = 0.019)
and OS (HR 2.79; 95% CI: 1.01 to 7.7); P = 0.048) was
found, with independence of tumour stage and hormonal
receptors status as depicted (Figure 5A).
Moreover, low expression levels of miR-141 (<0.145
relative expression value) in BC patient bloods
(Figure 3A and C) were found to be associated with
poorer progression-free survival time (mean: 169.37
versus 258.12 weeks; log-rank P = 0.028) and overall
survival time (mean: 216.01 versus 281.9 weeks; log-
rank P = 0.011). The median was not reached in the
high miR-141 subgroup. A decreased miR-141 level
was an indicator of a poor prognosis (HR for death,
2.76; 95% CI: 1.04 to 7.35; P = 0.042) independently of
stage and hormonal receptors. The association of low
miR-141 level with progression events when adjusted
for stage and hormonal receptors, however, did not
reach the statistical significance (Figure 5A; HR, 2.50;
95% CI: 0.96 to 6.53; P = 0.061).
To further evaluate whether blood miR-200 s deregu-
lation can predict BC prognosis, we next performed
survival analysis. Kaplan-Meier analysis showed that
Figure 2 (See legend on next page.)
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Figure 2 The role of blood miR-200c in breast cancer diagnosis. Receiver-operating characteristic (ROC) curve analysis (A) and odds ratio plot (B)
using blood miR-200c expression levels for discriminating breast cancer patients (n = 57) and healthy controls (n = 20). ROC curves and odds ratio
plots for discrimination of stage I-III BC from healthy controls (Cand D) and discrimination of stage I-II patients from healthy controls (E and F)
are also shown.
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low levels of miR-141 had significantly poorer
progression-free survival (P = 0.003; log-rank test;
Figure 4A) and overall survival (P < 0.0001; log-rank test;
Figure 4B). The results of the Cox proportional hazards
model incorporating a “poor prognostic” blood miRNA
signature are shown (Figure 5B). Multivariate analyses
included age, tumour stage, hormonal receptors and
microRNA levels. When paired in an interaction model,
high miR-200c and/or low miR-141 levels had a greater
association with decreased survival (HR, 3.89; 95% CI:
1.28 to 11.85; P =0.017) and shorter PFS (HR, 3.79; 95%
CI: 1.41 to 10.16; P =0.008) than either one alone.
Bioinformatics and microRNAs expression profiling
The miR-200c and miR-141 expression levels by oligo-
nucleotide microarray profiling of a panel of 20 BC
samples were retrieved from Mattie et al. [9]. This
series included three common phenotypes (9/20, ErbB2-
positive/ER-negative; 4/20, ErbB2-positive/ER-positive;
7/20, ErbB2-negative/ER-positive). The tumour miR-141
and miR-200c expressions were not associated with the
patient age, hormonal receptors, HER2 overexpression,
grade, proliferation index, or p53 mutational status.
The associations between miR-200c and miR-141
tumour expression, molecular subtypes and clinic and
pathological factors were assessed using the microRNA
expression data (GEO accession number GSE7842) pro-
vided by Blenkiron et al. [10], including 93 primary
breast tumour samples. For multiple comparisons, P
value was adjusted at 0.01. No significant associations
between miR-200c and miR-141 with tumour character-
istics such as molecular subtype, grade, stage, vascular
invasion, ER status, Nottingham Prognostic Index (NPI)
as well as TP53 status and HER2 overexpression were
found.
Two different datasets, which provide miRNAs expres-
sion data and clinical outcomes for BC patients, were
identified by MIRUMR online tool [26]. In the first data-
set, (accession number GSE37405) low miR-141 tumour
expression (P-values corrected by FDR, 0.03308) and
low miR-200c tumour expression (P-values corrected by
FDR, 0.02324) were associated with a reduced overall
survival in high-risk oestrogen receptor positive BC pa-
tients (Additional files 2 and 3). By contrast, in the sec-
ond dataset (GEO accession number GSE22216) that
included 189 early primary BC patients, no survival dif-
ferences were found according to miR-141 (P = 0.486)and miR-200c (P = 0.469) tumour expression (Additional
files 4 and 5).
We also used the PROGmiR tool [26] to create
Kaplan-Meier survival plots for miR-200c and miR-141
using the BC TCGA data. Overall survival at 3 and
5 years were not significantly different according tumour
levels of miR-200c and miR-141. However, with a longer
follow-up, the survival times became significantly better
in the high microRNA expressions groups. The hazard
ratio and P values for the proportional hazards model
are also given (Additional files 6, 7, 8 and 9).
The data about circulating miR-141 and miR-200c ex-
pression in three genome-wide studies deposited in
NCBI’s Gene Expression Omnibus (GEO) were retrieved
and analysed [33-35]. These studies included plasma
(two studies) or total blood (one study) of control
healthy women and early BC patients. The characteris-
tics and results of these studies are depicted (Additional
file 10). The levels of miR-141 and miR-200c in the
plasma were not significantly different between early BC
and controls. However, miR-141 was lower in total blood
of the BC cohort in comparison to controls (P = 0.029).
There was a trend to a negative correlation between cir-
culating miR-141 and miR-200c expression.
Discussion
Blood biomarkers that provide accurate diagnostic and
prognostic information for women with BC are urgently
required. MicroRNAs are deregulated in BC and histo-
logical and molecular subtypes are characterised by spe-
cific microRNA profiles. The deregulated expression of
miRNAs in both tumour tissues and the blood compart-
ment has led to the search for miRNAs to predict pres-
ence of cancer and indicate its overall prognosis [8-11].
To date, most of the studies in BC have focused on the
potential role of circulating (plasma or serum) miRNAs
as biomarkers for diagnosis and detection of early
disease and most of them are based on the testing of
multiple miRNAs, using high-throughput technologies
[19,33-35]. However, very few studies have explored the
capabilities of the blood miRNA expression in predicting
the clinical outcome of BC patients.
We hypothesize the deregulated expression of circulat-
ing and cellular miRNAs present in the whole blood can
identify the presence of BC, and could thus be developed
into a prognostic signature. Our study did not pursue
the current tendency to examine circulating miRNAs in
plasma or serum using high-throughput technologies. In
Table 2 Distribution of clinical and pathological parameters and levels of miR-200c and miR-141 in blood
Parameter n miR-200c P value miR-141 P value
Age (years) 0.190 0.240
<55 28 0.35 (0.72) 7.71 (12.47)
≥55 29 1.07 (1.74) 6.4 (15.1)
Menopause 0.572 0.258
Pre-menopausal 24 0.37 (0.68) 7.8 (12.96)
Post-menopausal 33 0.97 (1.68) 6.5 (14.5)
Histology 0.140* 0.712*
Ductal 50 0.69 (1.36) 7.26 (14.22)
Lobular 5 1.3 (1.95) 10.42 (14.67)
Other 2 0.01 (0.01) 0.2 (0.02)
Histological grade 0.106* 0.703*
1 7 1.79 (1.59) 3.84 (4.92)
2 25 0.36 (0.69) 4.19 (7.61)
3 23 0.77 (1.74) 11.72 (19.31)
TNM Stage 0.054 0.001
I-III 44 0.41 (0.83) 8.81 (15.16)
IV 13 1.75 (2.22) 1.06 (3.35)
Lymph nodes involved 0.216 0.014
No 20 1.06 (1.34) 1.53 (3.41)
Yes 37 0.53 (1.38) 10.02 (16.21)
Hormonal receptors 0.460 0.887
Positive 42 0.79 (1.52) 5.03 (9.35)
Negative 14 0.44 (0.86) 13.58 (21.85)
Oestrogen receptors 0.460 0.887
Positive 42 0.79 (1.52) 5.03 (9.35)
Negative 14 0.44 (0.86) 13.58 (21.85)
Progesterone receptors 0.653 0.371
Positive 29 0.59 (1.15) 5.96 (10.53)
Negative 27 0.82 (1.61) 8.46 (16.84)
HER2 0.833 0.037
Positive 14 0.88 (1.41) 1.24 (2.13)
Negative 42 0.64 (1.39) 9.14 (15.5)
MIB1 0.073 0.790
<25% 40 0.90 (1.55) 7.93 (15.24)
>25% 14 0.19 (0.65) 5.99 (10.26)
Type 0.809* 0.105*
Luminal 32 0.71 (1.52) 6.21 (10.4)
HER2 14 0.88 (1.41) 1.24 (2.13)
Triple negative 10 0.41 (0.86) 18.52 (24.35)
Residual disease 0.554 0.755
R0 27 0.52 (0.97) 8.69 (17.24)
R2 30 0.89 (1.66) 5.56 (9.73)
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Table 2 Distribution of clinical and pathological parameters and levels of miR-200c and miR-141 in blood (Continued)
Blood sampling^ 0.72 0.128
Before surgery 17 0.24 (0.5) 8.69 (17.24)
After surgery 27 0.52 (0.97) 8.99 (11.59)
The miRNAs relative expression levels (REL) are shown in arbitrary units. The data represent the mean (standard deviation). n indicates the number of patients
with data available. ^Timing of blood sampling before or after surgery is indicated for stages I to III patients only. Mann–Whitney test. *Kruskal-Wallis test.
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members of the miR-200 family of microRNAs, miR-
200c and miR-141, in the whole blood. Although the
feasibility of using miRNA expression profile in whole
blood as the basis for recognition of several diseases has
been demonstrated [18] its potential prognostic value in
cancer has not been comprehensively explored.
We found that miR-200c/miR-141 expression in the
blood of BC patients is deregulated comparing with con-
trols and, furthermore miR-200c and miR-141 levels
were associated with distinct disease-free survival and
overall survival of patients. Both of the univariate and
multivariate analyses indicated that miR-200c and miR-
141 blood levels were independent prognostic factors for
BC outcomes.
Our study showed miR-200c in blood was down-
regulated in stages I-III BC patients compared to age-
matched controls, discriminating these subsets with an
AUC-ROC of 0.85, and compared to patients with meta-
static disease. In contrast, a tendency to higher levels of
miR-141 in the blood of stage I-III BC patients in com-
parison with controls and stage IV patients was found.
MiR-200c and miR-141 were inversely correlated in the
blood of BC patients. Since these miRNAs measure-
ments could discriminate metastatic from early stage BC
patients and were associated with prognosis, miR-200c/
miR-141 blood levels may represent a BC-specific de-
regulation with potential functional consequences. In-
deed, the blood levels of miR-200c and miR-141 seem to
mirror the suggested biphasic role of this family of
microRNA during metastatic process [15,16].
In our BC cohort, neither miR-200c nor miR-141 cir-
culating levels were significantly associated with age,
menopausal status, histological subtype, tumour grade,Table 3 Correlations of clinical and laboratory parameters
and miRNA levels in blood of breast cancer patients
miR-200c miR-141
Spearman’s
Rho
P value Spearman’s
Rho
P value
Age 0.217 0.104 −0.208 0.12
Serum Ca 15.3 0.163 0.273 −0.361 0.013
Neutrophils Count −0.202 0.133 0.094 0.485
MIB1 tumour staining 0.085 0.538 −0.138 0.314
miR-141 −0.311 0.019hormonal receptors or IHC-based subtypes. The miR-
200c levels were numerically higher in stage IV and tu-
mours with lower MIB-1 staining. The miR-141 levels
were lower in stage IV, lymph node negative patients
and HER2 negative tumours. To validate these results,
we used previously reported data on miRNAs profiling
studies in BC. Similar to our findings, miR-200c and
miR-141 were not associated with molecular subtypes or
clinic and pathologic factors analysed [9,10].
One of the strengths of our study is the capability of
the whole-blood miR-200 and miR-141 deregulation to
predict PFS and OS was interrogated across a set of BC
patients with a comprehensive clinical, pathological and
long-term outcome data. Even with a relatively low sam-
ple size and few events in our patient population we
were able to demonstrate the correlation of these miR-
NAs to PFS and OS. MiR-200c was the most accurate
miRNA individually for predicting PFS and OS, and its
prediction accuracy increased by a small margin when
used in combination with miR-141. The poor-prognostic
profile defined by a high miR-200c and/or low miR-141
in the blood levels had a greater association with de-
creased survival and shorter PFS than either one alone,
and it was independent of age, tumour stage and hormo-
nal receptors status in the multivariate Cox’s model.
The sources of miRNAs in the blood are intriguing
and whether deregulation in circulating blood miRNAs
reflected similar changes in breast tumour tissues is
controversial. In that sense, it was surprising to detect
reduced concentrations of circulating miR-200c and
miR-141 in the whole blood of subsets of our BC patient
cohort comparing to age-matched healthy females. Re-
cently Dvinge et al. [17] have demonstrated a global
decrease in miRNA expression in breast tumours and de-
scribed that polycistronic miRNAs can show dependent, in-
dependent or even opposite expression patterns in BC.
Distinct patterns of miRNAs in circulation and BC tissue
had been reported both in murine BC models [36] and clin-
ical series [37].
Furthermore, a recent report suggests that normal and
malignant mammary epithelial cells release miRNA into
blood and fluids in a specific manner [20]. Microarray
and quantitative PCR analyses had indicated the breast
tumour cells selectively retain miR-141. In comparison,
miR-200c was highly released from cells. The low levels
of any particular miRNA in blood could also be caused
Figure 3 miR-200c and miR-141 expression levels measured in
peripheral blood are associated with poor prognosis in breast
cancer patients. Kaplan-Meier curves showing (A and B) the
progression-free survival (PFS) and (C and D) the overall survival
(OS) of 57 breast cancer patients with high or low blood expression
levels of microRNA. Continuous miRNA expression levels measured using
RT-qPCR were converted to dichotomous variables using the Cutoff
software (see text). The P values were computed using the Log-rank test.
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processing and exporting factors. Therefore, the extra-
cellular accumulation of mature miRNAs is regulated at
levels other than the primary transcript abundance in
the tumour cells. Roth et al. [38] had found a very low
expression of miR-141 in serum from BC patients andFigure 4 Poor prognostic blood miRNA signature. Kaplan-Meier
analysis and log-rank test showed that patients with higher levels
of blood miR-200c and/or low levels of miR-141 had significantly
poorer progression-free survival (A) and overall survival (B).
Figure 5 Blood miR-200c and/or miR-141 as prognostic factors in patients with breast cancer. Multivariate models showing the ability of high
miR-200c levels, low miR-141 levels, and the combination of both as prognostic factors for predicting progression free survival (A) and overall
survival (B) in breast cancer patients.
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in serum did not differ significantly between healthy
women and women with BC or between M0 and M1 pa-
tients. The one previous study that analyse miRNAs in
the whole blood in BC patients [34] have included only
early stages. They showed a down-regulation of miR-141
in the blood of BC patients while miR-200c was no dif-
ferentially expressed.
The analysis of miRNA obtained from whole-blood
may be advantageous in comparison with serum or
plasma determinations, detecting not only those miRNA
derived from blood cells comprising circulating tumour
cells, but also those secreted in sub-cellular particles
such as exosomes or associated with RNA binding
proteins and derived from diverse cells and tissues.
Compared to serum or plasma, whole blood is easier to
collect and has more RNA content, which facilitates
reliable and accurate global microRNA expressionmeasurements using less clinical material. Another
one of the crucial problems is the efficient and repro-
ducible extraction of small amounts of miRNA from
plasma or serum. Therefore, higher yields of miRNAs
had been consistently obtained from whole blood sam-
ples compared with matched serum or plasma and
lower quantification cycles occurred in whole blood
compared with matched serum and plasma samples in
RT-qPCR experiments [39].
One possibility is that circulating miRNAs are indica-
tive of CTCs and/or metastases. Supporting this con-
cept, Madhavan et al. [40] recently demonstrated that
plasmatic levels of miR-200 family members are surro-
gate markers for CTCs in heavily treated metastatic BC
patients and correlate with disease progression and over-
all survival. However, contradictory results have been de-
scribed. Roth et al. [38] did not observe any tendency of
higher miR-141 levels in serum of CTC-positive BC
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miR-200c transcript levels in the Ep-CAM+ circulating
tumour cells of metastatic BC patients compared with sam-
ples from healthy donors. In contrast, mR-141 transcript
levels were not differentially expressed. We hypothesised
that changes in miR-200c/miR-141 blood transcripts could
reflect at least in part, the presence of tumour cells that
have undergone or are undergoing epithelial-mesenchymal
(EMT) and mesenchymal-epithelial transitions (MET), a
dynamic process likely to be important for efficient meta-
static colonisation [42]. These previous reports and our re-
sults underline the complex relationships between disease
and changes in miRNA expression patterns in blood. Fur-
thermore, the contribution of systemic inflammatory, im-
munomodulatory or proangiogenic processes to the whole
blood microRNA profile cannot be ruled out. Maertzdorf
et al. [43] found that blood miR-200c and miR-141 expres-
sion levels are reduced in chronic inflammatory conditions.
In that sense, deregulation of miRNAs in the blood of BC
patients could be related, at least in part, to the host im-
mune and inflammatory context in response to BC.
It has been increasingly recognized that miR-200 fam-
ily of microRNAs plays an important role in the prolifer-
ation, invasiveness and migratory properties of BC cells
in cell lines [6,11-13] and experimental models; however,
a systematic investigation of how miR-200 s deregulation
affects the clinical outcome of BC patients has been
poorly defined.
In fact, the relative expression of the miR-200 family
in BC compared with normal breast tissue and even
though profiling data from primary and metastatic BC
samples have showed inconsistent results. Some authors
[44] have described the upregulation of miR-200c and
miR-141 during the transition from normal mammary
epithelia to atypical ductal hyperplasia, and maintained
their high expression profiles during later stages of
invasive ductal carcinoma. The miR-200 family of
microRNAs is differentially down-regulated in metastatic
lymph node metastasis compared to paired primary
tumour in BCs [45]. However, miR-200 expression was
found greater in metastases derived from BC than in pri-
mary tumours [16,46].
Overexpression of miR-200 s in primary tumour has
been associated with an increased risk of metastasis and
poor prognosis (in terms of metastasis-free survival) par-
ticularly in ER-positive breast cancers [16]. In contrast,
the bioinformatics analysis using MIRUMIR and PROG-
miR tools indicate an association between lower levels of
miR-200c and miR-141 in breast tumours and reduced
overall survival.
Although our preliminary results are promising, sev-
eral limitations in this study are addressed: (i) as the
sample size is still small, further validations in large co-
horts and in different ethnic groups are recommended;(ii) a remarkable limitation to this and other studies in
this field is the lack of standardized procedures. Differ-
ent pre-analytical and analytical factors affected the
quantification of circulating miRNA, including substrate
choice (whole blood, antibody-selected cells, plasma or
serum), stabilization reagents, centrifugation or filtration
to isolate plasma or serum, miRNA extraction proce-
dures, selection of endogenous internal controls, assay
choice, individual variation, and the effect of haemolysis.
Because miRNAs are present at lower concentrations in
plasma and serum than those found in whole blood, all
of these variables could increase the assays variability
and the stochastic effects when we quantified any micro-
RNA in serum or plasma samples comparing to whole
blood. Currently, there are no consistent reference genes
suitable for normalizing circulating microRNA expres-
sion. Thus, the selection of references to normalize
miRNA levels is still rather empirical. A combination of
miRNAs for normalization augments the reliability of
the data produced, and has been advocated by different
studies. In that sense, we used a combination of U6 and
5S as reference genes.
Finally, the clinical utility of any proposed biomarker
might be confirmed and validated in independent stud-
ies. In that sense our results regarding the prognostic
value of circulating miR-200c deregulation in BC are in
line with previous results including ours in gastric can-
cer and the recently reported works in oesophageal and
colorectal cancers [21,40,47,48].
In summary, the results of our pilot study indicate that
miR-200c and miR-141 levels are deregulated in the
blood of BC patients. Based on the differences between
cases and healthy controls, the blood miR-200c assay
holds promise as a detection marker in BC. Moreover,
we were able to verify that miR-200c and miR-141 in
whole blood are promising biomarkers of PFS and OS,
both independently and in combination. These results
will have to be further verified in large study cohorts
that include the different stages and molecular subtypes
of BC with adequate follow-up. A special attention to
technical challenges and standardization must be pur-
sued in the next validation studies. Furthermore, these
findings might have relevant implications for other epi-
thelial cancers where the miR-200 s family of microRNA
is also deregulated, widening this exciting and growing
field.
Conclusions
Breast cancer is the leading cause of cancer death in
women worldwide. Blood-borne metastases contribute
to the great majority of deaths. The discovery of specific
biomarkers characterizing the metastatic phenotype holds
the promises of personalised therapy and improved progno-
sis prediction. MicroRNAs can be detected in the blood
Antolín et al. BMC Cancer  (2015) 15:297 Page 14 of 15and studies indicate they are particularly stable and
abundant.
We hypothesised that the reverse-transcription quanti-
tative PCR detection of miR-200c and miR-141 in the
whole blood could be useful as clinical biomarker in
breast cancer patients.
Our results indicate that miR-200c and miR-141 levels
are deregulated in the blood of breast cancer patients.
Based on the differences between cases and controls, the
blood miR-200c assay holds promise as a diagnostic
marker. Moreover, miR-200c and miR-141 in whole
blood are promising biomarkers of progression-free and
overall survival, both independently and in combination.Additional files
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